Unzyme Laboratories is proud to announce that the U.S. Food and Drug Administration has granted approval for the CardioBoost Pro cardiovascular enhancement system. This approval represents years of dedicated research and positions Unzyme at the forefront of cardiac optimization technology.
Transforming Cardiovascular Health
CardioBoost Pro offers a minimally invasive solution for individuals seeking to optimize their cardiovascular performance. The system integrates seamlessly with the body’s existing circulatory infrastructure, providing measurable improvements in cardiac output, oxygen delivery efficiency, and overall cardiovascular resilience.
“This approval validates our approach to human enhancement,” said Erik Lindqvist, CEO of Unzyme Laboratories. “We’ve demonstrated that significant cardiovascular improvements are achievable safely and reliably. This is just the beginning.”
Clinical Trial Results
Our Phase III trials enrolled 1,847 participants across eight countries, generating robust data on both safety and efficacy:
- 23% average improvement in VO2 max
- 18% reduction in resting heart rate variability abnormalities
- Sustained benefits observed through 18-month follow-up
- Adverse event profile comparable to standard cardiac procedures
Availability
CardioBoost Pro will be available through certified cardiovascular centers beginning September 2020. We are currently establishing partnerships with leading cardiac care facilities to ensure broad access for qualified patients.
Interested patients should consult with their cardiologists to determine eligibility. Additional information is available through our clinical liaison team.
Looking Ahead
This FDA approval strengthens our commitment to advancing human cardiovascular potential. Our research teams continue developing next-generation technologies that will further expand what the human heart can achieve.
We thank the thousands of trial participants, clinical partners, and regulatory professionals whose dedication made this milestone possible.